Number of Sentinel Lymph Nodes Removed in Breast Cancer Patients – A Real-World Experience: Sentinel lymph node numbers

Tyrell Wees; Kehkashan Qureshi; Gopinath Narasimhan; Shahid Ahmed; Ambika Chandrasekhar; Osama Souied; Osama Ahmed; Shazia Mahmood; Ayesha Bashir; Muhammad Khan; Habib Khan; Haji Chalchal

doi:10.32768/abc.2025122164-170

Tyrell Wees ⁽¹⁾, Kehkashan Qureshi ⁽²⁾, Gopinath Narasimhan ⁽³⁾, Shahid Ahmed ⁽⁴⁾, Ambika Chandrasekhar ⁽⁵⁾, Osama Souied ⁽⁶⁾, Osama Ahmed ⁽⁷⁾, Shazia Mahmood ⁽⁸⁾, Ayesha Bashir ⁽⁹⁾, Muhammad Khan ⁽¹⁰⁾, Habib Khan ⁽¹¹⁾, Haji Chalchal ⁽¹²⁾

(1) College of Medicine, University of Alberta, Edmonton, Canada, Canada,

(2) College of Medicine, University of Saskatchewan, Saskatoon, Canada, Canada,

(3) Saskatchewan Cancer Agency, Regina, Saskatoon, Canada, Canada,

(4) College of Medicine, University of Saskatchewan, Saskatoon, Canada, Canada,

(5) Saskatchewan Cancer Agency, Regina, Saskatoon, Canada, Canada,

(6) College of Medicine, University of Saskatchewan, Saskatoon, Canada, Canada,

(7) College of Medicine, University of Saskatchewan, Saskatoon, Canada, Canada,

(8) College of Medicine, University of Saskatchewan, Saskatoon, Canada, Canada,

(9) College of Medicine, University of Saskatchewan, Saskatoon, Canada, Canada,

(10) College of Medicine, University of Saskatchewan, Saskatoon, Canada, Canada,

(11) College of Medicine, University of Saskatchewan, Saskatoon, Canada, Canada,

(12) College of Medicine, University of Saskatchewan, Saskatoon, Canada, Canada

https://doi.org/10.32768/abc.2025122164-170

Issue
Vol. 12 No. 2 (2025): May 2025

Submitted
October 31, 2024

Published
April 21, 2025

Keywords:

PDF

Abstract

Background: Retrieval of less than three Sentinel lymph nodes (SLN) has been shown to be associated with decrease disease specific survival. We aimed to find if the real-world experience replicates the data.

Methods: 529 patients with breast cancer (BC) who underwent sentinel lymph node biopsy (SLNB) from Jan 2010 to Dec 2014 were retrospectively reviewed. Data was analyzed using SAS 9.4 software. Chi square test was used if body mass index (BMI) influences the number of SLN retrieved and to detect difference between the variables of using blue dye and radioisotopes for detecting SLN.

Results: Proportion of one, two and three or more SLN retrieval was 21, 35 and 44% respectively with the median number two. There was no difference in the number of lymph nodes retrieved if the radioisotope (RI) was used alone or in combination with blue dye (BD). P value of 0. 88. No change in median number of SLN retrieved in different quadrants of the breast was noted. We obtained body mass index (BMI) in 454 patients. The rate of more than two SLN retrieval in patients with normal BMI was 16%. In overweight 12% and obese 18%. We compared SLN= (one, two) vs. SLN= two + group which are crossed tabbed against three BMI categories of normal, overweight and obese. This was statistically significant, p-value of 0. 028.

Conclusion: The real-world data suggest sub-optimal retrieval of number of median SLN compared to clinical trials. Higher BMI was associated with less than three SLN retrieved.

References

Lyman GH, Giuliano AE, Somerfield MR, Benson AB, Bodurka DC, Burstein HJ, et al. American Society of Clinical Oncology Guideline Recommendations for Sentinel Lymph Node Biopsy in Early-Stage Breast Cancer. J Clin Oncol. 2005 Oct 20;23(30):7703–20. doi: 10.1200/JCO.2016.71.0947.

Bonneau C, Bendifallah S, Reyal F, Rossi L, Rouzier R. Association of the number of sentinel lymph nodes harvested with survival in breast cancer. Eur J Surg Oncol EJSO. 2015 Jan;41(1):52–8. doi: 10.1016/j.ejso.2014.11.004.

Cantin J, Scarth H, Levine M, Hugi M, Steering Committee on Clinical Practice Guidelines for the Care and Treatment of Breast Cancer. Clinical practice guidelines for the care and treatment of breast cancer: 13. Sentinel lymph node biopsy. CMAJ Can Med Assoc J J Assoc Medicale Can. 2001 Jul 24;165(2):166–73.

Krag DN, Anderson SJ, Julian TB, Brown AM, Harlow SP, Costantino JP, et al. Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial. Lancet Oncol. 2010 Oct;11(10):927–33. doi: 10.1016/S1470-2045(10)70207-2.

Ashikaga T, Krag DN, Land SR, Julian TB, Anderson SJ, Brown AM, et al. Morbidity results from the NSABP B‐32 trial comparing sentinel lymph node dissection versus axillary dissection. J Surg Oncol. 2010 Aug;102(2):111–8. doi: 10.1002/jso.21535.

Mansel RE, Fallowfield L, Kissin M, Goyal A, Newcombe RG, Dixon JM, et al. Randomized Multicenter Trial of Sentinel Node Biopsy Versus Standard Axillary Treatment in Operable Breast Cancer: The ALMANAC Trial. JNCI J Natl Cancer Inst. 2006 May 3;98(9):599–609. doi: 10.1093/jnci/djj158.

Veronesi U, Viale G, Paganelli G, Zurrida S, Luini A, Galimberti V, et al. Sentinel Lymph Node Biopsy in Breast Cancer: Ten-Year Results of a Randomized Controlled Study. Ann Surg. 2010 Apr;251(4):595–600. doi: 10.1097/SLA.0b013e3181c0e92a.

Purushotham AD, Upponi S, Klevesath MB, Bobrow L, Millar K, Myles JP, et al. Morbidity After Sentinel Lymph Node Biopsy in Primary Breast Cancer: Results From a Randomized Controlled Trial. J Clin Oncol. 2005 Jul 1;23(19):4312–21. doi: 10.1097/SLA.0b013e3181c0e92a.

Wetzig N, Gill PG, Espinoza D, Mister R, Stockler MR, Gebski VJ, et al. Sentinel-Lymph-Node-Based Management or Routine Axillary Clearance? Five-Year Outcomes of the RACS Sentinel Node Biopsy Versus Axillary Clearance (SNAC) 1 Trial: Assessment and Incidence of True Lymphedema. Ann Surg Oncol. 2017 Apr;24(4):1064–70. doi: 10.1245/s10434-016-5669-2

Zavagno G, De Salvo GL, Scalco G, Bozza F, Barutta L, Del Bianco P, et al. A Randomized Clinical Trial on Sentinel Lymph Node Biopsy Versus Axillary Lymph Node Dissection in Breast Cancer: Results of the Sentinella/GIVOM Trial. Ann Surg. 2008 Feb;247(2):207–13. doi: 10.1097/SLA.0b013e31812e6a73.

Giuliano AE. Axillary Dissection vs No Axillary Dissection in Women With Invasive Breast Cancer and Sentinel Node Metastasis: A Randomized Clinical Trial. JAMA. 2011 Feb 9;305(6):569. doi: 10.1001/jama.2011.90.

Giuliano AE, McCall L, Beitsch P, Whitworth PW, Blumencranz P, Leitch AM, et al. Locoregional Recurrence After Sentinel Lymph Node Dissection With or Without Axillary Dissection in Patients With Sentinel Lymph Node Metastases: The American College of Surgeons Oncology Group Z0011 Randomized Trial. Ann Surg. 2010 Sep;252(3):426–33. doi: 10.1097/SLA.0b013e3181f08f32.

Galimberti V, Cole BF, Zurrida S, Viale G, Luini A, Veronesi P, et al. Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23–01): a phase 3 randomised controlled trial. Lancet Oncol. 2013 Apr;14(4):297–305. doi: 10.1016/S1470-2045(13)70035-4.

Donker M, Van Tienhoven G, Straver ME, Meijnen P, Van De Velde CJH, Mansel RE, et al. Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial. Lancet Oncol. 2014 Nov;15(12):1303–10. doi: 10.1016/S1470-2045(14)70460-7.

Hutchinson JR, Chagpar AB, Scoggins CR, Martin RCG, Carlson DJ, Laidley AL, et al. Surgeon and community factors affecting breast cancer sentinel lymph node biopsy. Am J Surg. 2005 Dec;190(6):915–9. doi: 10.1016/j.amjsurg.2005.08.018.

Krag D, Weaver D, Ashikaga T, Moffat F, Klimberg VS, Shriver C, et al. The Sentinel Node in Breast Cancer — A Multicenter Validation Study. N Engl J Med. 1998 Oct;339(14):941–6. doi: 10.1056/NEJM199810013391401.

Cipolla C, Galvano A, Vieni S, Saputo F, Lupo S, Latteri M, et al. Effects of the number of removed lymph nodes on survival outcome in patients with sentinel node-negative breast cancer. World J Surg Oncol. 2021 Dec;19(1):306. doi: 10.1186/s12957-021-02418-9.

Cody HS, Fey J, Akhurst T, Fazzari M, Mazumdar M, Yeung H, et al. Complementarity of Blue Dye and Isotope in Sentinel Node Localization for Breast Cancer: Univariate and Multivariate Analysis of 966 Procedures. Ann Surg Oncol. 2001 Jan;8(1):13–9. doi: 10.1007/s10434-001-0013-9.

Krag DN, Anderson SJ, Julian TB, Brown AM, Harlow SP, Ashikaga T, et al. Technical outcomes of sentinel-lymph-node resection and conventional axillary-lymph-node dissection in patients with clinically node-negative breast cancer: results from the NSABP B-32 randomised phase III trial. Lancet Oncol. 2007 Oct;8(10):881–8. doi: 10.1016/S1470-2045(07)70278-4.

Chagpar AB, Martin RC, Scoggins CR, Carlson DJ, Laidley AL, El-Eid SE, et al. Factors predicting failure to identify a sentinel lymph node in breast cancer. Surgery. 2005 Jul;138(1):56–63. doi: 10.1016/j.surg.2005.03.003.

Derossis AM, Fey JV, Cody HS, Borgen PI. Obesity influences outcome of sentinel lymph node biopsy in early-stage breast cancer. J Am Coll Surg. 2003 Dec;197(6):896–901. doi: 10.1016/j.jamcollsurg.2003.08.005.

Gawlick U, Mone MC, Nelson ET, Hansen HJ, Nelson EW. Success in sentinel lymph node procedures in obese patients with breast cancer. Am J Surg. 2010 Dec;200(6):707–11. doi: 10.1016/j.amjsurg.2010.07.031,

Hughes M, Goffman TG, Perry RR, Laronga C. Obesity and lymphatic mapping with sentinel lymph node biopsy in breast cancer. Am J Surg. 2004 Jan;187(1):52–7. doi: 10.1016/j.amjsurg.2003.04.004.

https://www.saskatchewan.ca/government/government-data/bureau-of-statistics/population-and-census.

Gentilini OD, Botteri E, Sangalli C, Galimberti V, Porpiglia M, Agresti R, et al. Sentinel Lymph Node Biopsy vs No Axillary Surgery in Patients With Small Breast Cancer and Negative Results on Ultrasonography of Axillary Lymph Nodes: The SOUND Randomized Clinical Trial. JAMA Oncol. 2023 Nov 1;9(11):1557. doi: 10.1001/jamaoncol.2023.3759.

Reimer T, Stachs A, Veselinovic K, Kühn T, Heil J, Polata S, et al. Axillary Surgery in Breast Cancer — Primary Results of the INSEMA Trial. N Engl J Med. 2024 Dec 12;NEJMoa2412063. doi: 10.1056/NEJMoa2412063.

Authors

Tyrell Wees

College of Medicine, University of Alberta, Edmonton, Canada

https://orcid.org/0000-0002-8977-949X

Kehkashan Qureshi